Kura Oncology (NASDAQ:KURA) CEO Purchases 100,000 Shares

Key Points

• CEO Troy Edward Wilson purchased 100,000 Kura Oncology shares at an average price of $12.39, investing $1.239 million and increasing his direct ownership by 26.37% to 479,194 shares. He also bought 100,000 shares the prior week at $11.12 each.
• Kura Oncology shares rose 4.3% to $12.40, near the company’s 12-month high of $12.90, while trading volume exceeded its average.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $25.40. In its latest quarter, Kura reported a smaller-than-expected loss and revenue slightly above estimates, although it remains unprofitable.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) CEO Troy Edward Wilson acquired 100,000 shares of the stock in a transaction dated Monday, August 24th. The stock was acquired at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the acquisition, the chief executive officer directly owned 479,194 shares of the company's stock, valued at $5,937,213.66. The trade was a 26.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Troy Edward Wilson also recently made the following trade(s):

• On Monday, August 17th, Troy Edward Wilson bought 100,000 shares of Kura Oncology stock. The shares were acquired at an average price of $11.12 per share, with a total value of $1,112,000.00.

Kura Oncology Stock Up 4.3%

Kura Oncology stock traded up $0.51 during mid-day trading on Monday, reaching $12.40. The company's stock had a trading volume of 2,673,296 shares, compared to its average volume of 1,620,411. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.68 and a beta of 0.38. Kura Oncology, Inc. has a 12 month low of $7.36 and a 12 month high of $12.90. The business's 50 day simple moving average is $10.53 and its 200 day simple moving average is $9.47. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to analysts' expectations of $20.16 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc raised its holdings in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company's stock valued at $25,000 after purchasing an additional 1,284 shares during the last quarter. Royal Bank of Canada boosted its holdings in Kura Oncology by 7.6% during the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company's stock worth $203,000 after purchasing an additional 1,375 shares during the last quarter. Allworth Financial LP grew its position in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company's stock worth $43,000 after purchasing an additional 1,553 shares in the last quarter. Focus Partners Advisor Solutions LLC increased its stake in Kura Oncology by 7.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company's stock valued at $238,000 after buying an additional 1,682 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Kura Oncology by 10.0% during the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company's stock worth $193,000 after buying an additional 1,692 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on KURA shares. Citizens Jmp reissued a "market outperform" rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday. Wedbush lifted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, May 28th. Wall Street Zen raised shares of Kura Oncology from a "strong sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and a consensus price target of $25.40.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source